C-Path’s TRxA announces its 2024 global 'Request for Proposals' from academic investigators working to advance drug development projects

New funding oppurtunity!

2024-01-22

(Press-News.org) Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. These BRIDGe awards are designed to support academic researchers in traversing the drug development valley of death by providing funding and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.

Maaike Everts, Ph.D., Executive Director of C-Path’s TRxA, expressed her enthusiasm for this next cycle of awards, stating, “The impactful progress in our currently funded projects serves as a testament to the power of collaboration in drug discovery and development; we look forward to identifying the exceptional projects that will emerge from this cycle and, together, shaping the next generation of life changing medicines.”

As a nonprofit drug accelerator, TRxA provides the following for principal investigators who are selected to receive a BRIDGe award:

Tactical and strategic drug discovery and development expertise, including regulatory science considerations. Resources and hands-on guidance, working closely with academic researchers to develop comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies to invest in clinical trials. Engagement of contract research organizations (CRO) to perform critical discovery phase experiments and/or validate academic studies. More information about this funding opportunity is available in TRxA’s Guidance Document for Applicants. Also, be sure to register for the 2024 TRxA Funding Opportunities webinar at 10 a.m. ET, Tuesday, January 30. Content will include an overview of the types of projects TRxA funds, eligibility criteria for TRxA awards, and details about how to apply before the first submission deadline of March 31, 2024. The webinar will conclude with a live Q&A.

To learn more, visit c-path.org/programs/trxa or email TRxA at trxa@c-path.org.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

About C-Path’s Translational Therapeutics Accelerator (TRxA)

Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) is a not-for-profit global drug accelerator focused on supporting academic scientists in advancing novel therapeutics from university-based labs to drug development pipelines of pharmaceutical companies and, ultimately, the clinic. As a neutral convener of patient groups, academia, pharmaceutical companies and regulatory agencies, C-Path brings a breadth of scientific and drug development planning not available in other accelerator programs. TRxA is uniquely situated to leverage the expertise available through C-Path’s >20 disease-based consortia, as well as regulatory expertise and project management, to empower academic investigators to succeed in bringing safe and effective treatments to patients. For more information, visit c-path.org/trxa or email trxa@c-path.org.

Contact:

Kissy Black
C-Path
615.310.1894
kblack@c-path.org

END

ELSE PRESS RELEASES FROM THIS DATE:

RESEARCH ALERT: Melanoma overdiagnosis soars among white Americans, study finds

2024-01-22

AUSTIN, Texas — More than half of all melanoma diagnoses among white Americans may be overdiagnosed, according to a new study led by a researcher at Dell Medical School at the University of Texas at Austin. “Cases of cutaneous melanoma have risen significantly in the U.S. over the last 40 years, without an equivalent rise in mortality— which points to overdiagnosis,” said Ade Adamson, M.D., M.P.P., lead author of the study and an assistant professor in the Department of Internal Medicine at Dell Med. “Overdiagnosis happens when a melanoma is diagnosed that is actually harmless. That means the patient ...

Older adults spend 3 weeks each year receiving health care outside of the home

2024-01-22

Embargoed for release until 5:00 p.m. ET on Monday 22 January 2024  Annals of Internal Medicine Tip Sheet   @Annalsofim Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent. ---------------------------- 1. Older adults spend 3 weeks each year receiving ...

EHR workload continues to grow for primary care physicians

2024-01-22

The study evaluated recent trends in primary care physicians’ (PCPs) electronic health record (EHR) workload. Prior to and early in the COVID-19 pandemic, PCPs spent more time in the EHR and received more messages than physicians in other specialties, but it is unclear if the pandemic further accelerated the growth of PCPs’ EHR workload. Researchers observed EHR usage of 141 academic PCPs practicing family medicine, internal medicine, and general pediatrics within the University of Wisconsin-Madison health system, which cares for nearly 300,000 primary care patients per year. This longitudinal study compared the amount of time participating ...

Clear and open communication with care teams could improve the birthing experience for Black people

2024-01-22

This study explored the perspectives of Black birthing people on how better communication with care teams may have improved their birth experiences. Researchers interviewed 30 non-Hispanic Black, English-language–proficient, low-income birthing people in the Philadelphia, Pennsylvania, area, all of whom were insured by Medicaid. All gave birth to preterm infants before 34 weeks gestation, or before 36 weeks gestation to birthing people with a modifiable risk factor such as high blood pressure. The interviews uncovered three main themes regarding the quality of communication with their care teams and the effect on their experiences: ...

A simple three-question screening tool may help to identify precarious employment among primary care patients

2024-01-22

Precarious employment, defined by temporary contracts, unstable employment, or job insecurity, is increasingly common and is associated with inconsistent access to health insurance, lower incomes, and greater exposure to physical hazards and psychological stress. A team of researchers in Toronto, Canada, created and tested a new three-question screening tool to help primary care clinics identify these patients. The screener included the following three questions: 1) non-standard employment (Are you currently employed in a casual, short-term, or temporary position?); 2) violations of occupational health ...

Primary care physicians and urologists work together to provide optimal care for men with low-risk prostate cancer

2024-01-22

This study considers the perspectives of primary care physicians (PCPs) and urologists on what facilitates and what creates barriers to active surveillance (AS) care for men with low-risk prostate cancer. Researchers conducted in-depth, semi-structured interviews with 19 PCPs (9 female, 4 in community practices, 15 in academic medical centers) and 15 urologists (3 female, 5 in private practice, 3 in academic medical centers) between June 2020 and March 2021. Their goal was to assess interviewees’ knowledge of AS, what factors they felt influence adherence to follow-up ...

Patients who obtained telemedicine medication abortions (TeleMAB) through primary care have positive feelings about their experience

2024-01-22

This study explores patients’ experiences and perspectives on obtaining telemedicine medication abortions (TeleMAB) through their primary care health system. Researchers conducted in-depth phone interviews with 14 English, Spanish, and/or Portuguese-speaking patients, ranging in age from 26 to 42, who received a TeleMAB between July 2020 and December 2021 from a large primary care safety-net community health system in Massachusetts. Thirteen of the interviewees provided demographic information. All 13 identified as female, and 10 had children ...

An update on a 2015 report shows that gabapentinoid usage in the U.S. has continued to climb

2024-01-22

Gabapentinoids are commonly prescribed for an array of off-label conditions, including management of chronic pain. Updating their 2015 report on gabapentinoid usage in the U.S., researchers used the 2002–2021 Medical Expenditure Panel Survey (MEPS) to investigate the proportion of the adult population using gabapentinoids, medications, and diagnoses associated with users, and the likelihood of starting, stopping, or continuing gabapentinoids. They found that gabapentinoid use has increased from 4.0% in 2015 to 4.7% in 2021. ...

The serious risks and high costs of monoclonal antibodies may outweigh the benefits for patients with Alzheimer dementia

2024-01-22

Researchers performed a meta-analysis of randomized trial studies that compared the use of amyloid-reducing monoclonal antibodies (MABs) in patients with Alzheimer dementia at a dose consistent with that used in Phase 3 or FDA approval trials with the use of a placebo. Their purpose was to evaluate clinically meaningful benefits and harms of MABs to these patients. For inclusion in this meta-analysis, the RCT studies had to include adult participants with cognitive impairment or Alzheimer disease of any severity and report at least one clinically relevant benefit or harm to participants after at least one year. The research team identified 19 such publications that evaluated ...

Annals of Family Medicine January/February 2024 Tip Sheet

2024-01-22

EHR Workload Continues to Grow for Primary Care Physicians The study evaluated recent trends in primary care physicians’ (PCPs) electronic health record (EHR) workload. Prior to and early in the COVID-19 pandemic, PCPs spent more time in the EHR and received more messages than physicians in other specialties, but it is unclear if the pandemic further accelerated the growth of PCPs’ EHR workload. Researchers observed EHR usage of 141 academic PCPs practicing family medicine, internal medicine, and general pediatrics within the University of Wisconsin-Madison health system, which ...

C-Path’s TRxA announces its 2024 global 'Request for Proposals' from academic investigators working to advance drug development projects

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: